产品描述: | SC-43, a Sorafenib derivative, is a potent and orally active SHP-1 (PTPN6) agonist. SC-43 inhibits the phosphorylation of STAT3 and induces cell apoptosis. SC-43 has anti-fibrotic and anticancer effects |
靶点: |
SHP-1;p-STAT3;Apoptosis; Phosphatase; STAT |
体内研究: |
SC-43 (10-30 mg/kg; oral gavage; daily; for 23 days; male NCr athymic nude mice) treatment exhibits xenograft tumor growth inhibition, p-STAT3 reduction and SHP-1 activity elevation. Animal Model: Male NCr athymic nude mice (5-7 weeks of age) injected with HuCCT-1 cells Dosage: 10 mg/kg or 30 mg/kg Administration: Oral gavage; daily; for 23 days Result: Exhibited xenograft tumor growth inhibition, p-STAT3 reduction and SHP-1 activity elevation. |
参考文献: |
1. Ming-Hung Hu, et al. Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma. Oncotarget. 2017 May 10;8(39):65077-65089. 2. Tung-Hung Su, et al. Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis. Sci Rep. 2017 May 11;7(1):1728. |
溶解性: |
Soluble in DMSO |
保存条件: |
-20℃ |
配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
1 mM |
2.316 ml |
11.58 ml |
23.159 ml |
5 mM |
0.463 ml |
2.316 ml |
4.632 ml |
10 mM |
0.232 ml |
1.158 ml |
2.316 ml |
50 mM |
0.046 ml |
0.232 ml |
0.463 ml |
|
注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |